Happiness Biotech Announces Registered Direct Offering of up to 4.2 Million Ordinary Shares to Strategic Investors
NANPING, China, Jan. 4, 2021 /PRNewswire/ — Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that it has entered into a securities purchase agreement with certain non-U.S. strategic investors for a registered direct placement. The Company expects to issue up to 4,200,000 ordinary shares in multiple installments and the purchase price will be the volume-weighted average trading price of the ordinary shares for the consecutive five trading days immediately prior to the date when the Company delivers a notice of purchase to the investors. If the Company offers the entire 4.2 million shares, assuming the ordinary share trades at the current level, the expected gross proceeds of the offering will be approximately $7 million.
The Company expects to use the proceeds to further develop and expand the business carried out by its wholly-owned subsidiary in China, Happy Buy (Fujian) Internet Technology Co., Limited, including social e-commerce, content e-commerce, e-commerce livestreaming and marketing on social media such as TikTok, etc., and for working capital and general corporate purposes.
This offering is being made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-250026) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on November 23, 2020. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
“We are glad that more strategic investors have seen the value and potential of Happy Buy. These investors have extensive experience investing in the e-commerce industry. This transaction not only brings more capital for the Company, but also brings more recognition in the e-commerce industry for Happy Buy. We believe that with this financing, Happy Buy will achieve faster growth and continue the strong momentum,” said Mr. Xuezhu Wang, CEO of the Company.
About Happiness Biotech Group Limited
Headquartered in Nanping, China, Happiness Biotech Group Limited is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company’s goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 PRC National Medical Products Administration registered “Blue-Cap” SKUs of nutraceutical and dietary supplements products. For more information, please visit: www.happ.org.cn.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China, the COVID-19 outbreak and its impact on our operations and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
View original content:http://www.prnewswire.com/news-releases/happiness-biotech-announces-registered-direct-offering-of-up-to-4-2-million-ordinary-shares-to-strategic-investors-301200018.html
SOURCE Happiness Biotech Group Limited
